Florida’s use of new and off-label COVID-19 treatments – precision vaccinations
Florida’s use of new and off-label COVID-19 treatments – precision vaccinations

Florida’s use of new and off-label COVID-19 treatments – precision vaccinations

(precision vaccinations)

The Florida Department of Health recently issued one Provider warning regarding the use of new and off-label COVID-19 treatments.

On February 24, 2022, this warning stated, “when physicians recommend COVID-19 treatment options for patients ‘individualized health needs, physicians should exercise their individual clinical judgment and expertise based on their patients’ needs and preferences.”

“COVID-19 prevention and treatments prescribed under the guidance of a licensed physician can save lives and mitigate the effects of COVID-19 on Floridians.”

“The State of Florida has widespread natural and vaccine-induced immunity,” commented Florida State Surgeon General Dr. Joseph A. Ladapo in a related video. “Evidence suggests that most secondary transmissions occur early.”

“Our state will continue to make decisions for Floridians rooted in sound science, not fear, whether they work or go to school.”

Provider Alert went on to say, “When recommending COVID-19 treatment options for patients ‘individualized health needs, physicians should exercise their individual clinical judgment and expertise based on their patients’ needs and preferences.”

“These options may include new treatments supported by quality evidence, with appropriate patient-informed consent, including off-label use or as part of a clinical trial.”

E.g:

  • Fluvoxamine
  • Inhaled Budesonide

‘We are committed to protecting the comprehensive practice of healthcare in an environment where treatments continue to evolve, and expect Florida healthcare providers to stay informed about the availability of COVID-19 therapy optionsincluding:

“As guidance continues to evolve, health care physicians should maintain and maintain an in-depth awareness of the data surrounding COVID-19 treatment options.”

‘Some treatments should be carefully evaluated before administration for both indication and timing, such as Remdesivir (Veklury) in hospital settings (which recently received FDA approval for outpatient COVID-19 treatment) and lopinavir / ritonavir. ‘

“It is the responsibility of healthcare practitioners to be informed about evolving and new patient care options for COVID-19 to assess risks and benefits for individual patients, which often vary from patient to patient,” this Florida Alert stated.

Note: Florida’s allocation of COVID-19 treatments for week 21-27. February 2022 is published on this US HHS form.

Leave a Reply

Your email address will not be published.